Marizyme, Inc. MRZM

Full chart Compare

Set alert

0.00 USD 0.00 (+0.00%)

At closeNov 2, 2026, 4:00 PM EST

0.0081 Day range 0.0081

0.0003 52-week range 0.0081

YTD: 0.00%
1 year: 0.00%

News

2 years ago globenewswire.com Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics,…
3 years ago globenewswire.com Marizyme CEO Delivers Business Update JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the…
3 years ago globenewswire.com Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries
4 years ago seekingalpha.com U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals
4 years ago globenewswire.com Marizyme is Pleased to Announce the Appointment of David Barthel as CEO JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief…
5 years ago prnewswire.com Marizyme, Inc. Issues Letter to Shareholders JUPITER, Fla., March 31, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in…
5 years ago prnewswire.com Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in…
5 years ago prnewswire.com Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in…
5 years ago prnewswire.com Marizyme Announces Approval for DuraGraft® in India JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in…
5 years ago prnewswire.com Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting,…
6 years ago benzinga.com Stocks That Hit 52-Week Highs On Friday